- Home
- VMD vs ALDX Comparison
VMD vs ALDX Comparison
Compare VMD & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- ALDX
- Stock Information
- Founded
- VMD 2006
- ALDX 2004
- Country
- VMD United States
- ALDX United States
- Employees
- VMD N/A
- ALDX N/A
- Industry
- VMD
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- ALDX Health Care
- Exchange
- VMD Nasdaq
- ALDX Nasdaq
- Market Cap
- VMD 280.4M
- ALDX 314.6M
- IPO Year
- VMD N/A
- ALDX 2014
- Fundamental
- Price
- VMD $6.86
- ALDX $5.14
- Analyst Decision
- VMD
- ALDX Strong Buy
- Analyst Count
- VMD 0
- ALDX 2
- Target Price
- VMD N/A
- ALDX $9.50
- AVG Volume (30 Days)
- VMD 167.2K
- ALDX 666.3K
- Earning Date
- VMD 11-05-2025
- ALDX 11-06-2025
- Dividend Yield
- VMD N/A
- ALDX N/A
- EPS Growth
- VMD 47.14
- ALDX N/A
- EPS
- VMD 0.34
- ALDX N/A
- Revenue
- VMD $240,884,000.00
- ALDX N/A
- Revenue This Year
- VMD $19.22
- ALDX N/A
- Revenue Next Year
- VMD $17.51
- ALDX $63.48
- P/E Ratio
- VMD $20.27
- ALDX N/A
- Revenue Growth
- VMD 17.11
- ALDX N/A
- 52 Week Low
- VMD $5.93
- ALDX $1.14
- 52 Week High
- VMD $9.81
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- VMD 50.59
- ALDX 44.60
- Support Level
- VMD $6.66
- ALDX $5.06
- Resistance Level
- VMD $7.10
- ALDX $5.40
- Average True Range (ATR)
- VMD 0.17
- ALDX 0.29
- MACD
- VMD 0.01
- ALDX -0.03
- Stochastic Oscillator
- VMD 45.45
- ALDX 40.58
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.